Abstract 1584P
Background
The impact of TB (which contributes to both financial and time toxicities) on cancer treatment and outcomes, especially in RLS remains largely understudied. We assessed the impact of TB on the outcomes of patients with CRC treated at a regional cancer center in RLS.
Methods
All patients with newly diagnosed CRC in 2022 at the State Cancer Institute, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, North India were enrolled. TB was recorded as the average time required to traverse the shortest distance between the cancer center and the place of the patient’s residence.
Results
263 patients (42.6% females) with CRC were included, including patients who travelled from their homes (group A) and those who rented apartments near the hospital to complete treatment (group B). Group A patients (N=178) travelled 22 km (48 mins) [median] to reach the cancer center while Group B patients (N=85) resided 75 km (130 mins) [median] away from the hospital. Travel time did not correlate with symptom duration prior to diagnosis of CRC. In group A, patients with highest TB (Q4 travel time) had poorer outcomes than other patients (Q1-Q3 of travel time) (18-month OS of 65% v 83.6%, adjusted HR 2.5 [95% CI 1.2 to 5.2]) (Table). 18-month OS in group B was higher than that for group A patients (85.6% v 78.9%, p=0.056). Table: 1584P
Predictors of OS in patients with CRC [data expressed as HR (95% CI), p-value]
| Parameter | Group A | Group B | ||
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |
| 1. Age ≥50 years | 1.6 (0.8 to 3.5), 0.2 | 1.3 (0.3 to 6.4), 0.8 | ||
| 2. Female sex | 0.8 (0.4 to 1.5), 0.4 | 0.5 (0.1 to 2.3), 0.3 | ||
| 3. Presence of comorbidity | 1.1 (0.5 to 2.1), 0.8 | 0.0 (0.0 to 8.0), 0.2 | ||
| 4. ECOG >1 | 3.6 (1.7 to 7.5), 0.001 | 3.4 (1.4 to 7.9), 0.005 | 0.8 (0.1 to 6.7), 0.9 | |
| 5. Left vs right colon | 1.3 (0.5 to 3.5), 0.6 | 1.6 (0.12 to 13.4), 0.7 | ||
| 6. Metastatic disease | 8.1 (4.0 to 16.2), ConclusionsOur study demonstrates that TB is significantly associated with poorer outcomes in patients with CRC. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyS.Z. Banday. FundingHas not received any funding. DisclosureB. Gyawali: Financial Interests, Personal, Writing Engagement, For writing Medscape Columns: Medscape; Financial Interests, Personal, Invited Speaker, For giving invited talks and grand rounds at universities, cancer centers and professional societies: Various academic and professional organizations; Financial Interests, Personal, Other, Consulting services: Vivio Health; Non-Financial Interests, Member: ASCO, IASLC, JSMO. All other authors have declared no conflicts of interest. Resources from the same session1553P - Access to EMA approved drugs in Europe, disparities across a borderPresenter: Orla Fitzpatrick Session: Poster session 10 1554P - Co payments in cancer patients: Analysis and estimating OOPPresenter: Krishnamani Kalpathi Session: Poster session 10 1555P - Estimating the social value of immuno-oncology (IO) therapies in JapanPresenter: Tomoya Ohno Session: Poster session 10 1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and EuropePresenter: Jose Tapia Session: Poster session 10 1557P - The use of patient experience in UK NICE decision making in oncologyPresenter: Noemi Muszbek Session: Poster session 10 1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian populationPresenter: Elaria Yacoub Session: Poster session 10 1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unitPresenter: Jonathan Poon Session: Poster session 10 1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriersPresenter: Alberta Ferrari Session: Poster session 10 1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening PilotPresenter: Tanel Laisaar Session: Poster session 10 1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in EstoniaPresenter: Anni Lepland Session: Poster session 10 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||